No moderate or severe flares one year prior to screening
Taking ≥ 200 HCQ daily for ≥ 7 years
You may not be if
Any patient that does not attain stable disease status by DORIS
Ophthalmologic evidence of retinopathy (these patients would be advised to discontinue HCQ and therefore unethical to randomize for this study)
Clinical SLEDAI \> 0
Taking \> 5 mg/day prednisone
Taking any immunosuppressive drugs or biological agents (including: methotrexate, azathioprine, mycophenolate mofetil, mycophenolic acid, leflunomide, cyclosporine, cyclophosphamide, tacrolimus, rituximab, and belimumab)
Any reason the treating rheumatologist is concerned about ongoing activity not captured by SLEDAI
HCQ level \< 100 ng/ml as this would support noncompliance and less reliance on HCQ to control activity
Patient unwilling or unable to comply with study procedures for any reason
Any indications of potentially diminished capacity, such as a diagnosis of dementia or cognitive impairment (including, but not limited to stroke-related cognitive impairment)
